SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku shares recently surged following reports that the streaming company is exploring a potential sale, with major media firms reportedly among the interested parties. Investors are actively debating the likelihood of a buyout, weighing potential premium pricing against Roku's strengthening platform growth and its critical position as a gatekeeper in the connected TV advertising ecosystem.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending following an overwhelming shareholder vote to approve the $110 billion merger with Paramount Skydance, marking a major milestone for this media megadeal. While the merger faces continued antitrust scrutiny from regulators and some pushback from Hollywood creators, the market is actively monitoring the deal's path to closing and the implications for industry consolidation.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor (TAO) is trending as investors focus on its integration into the Solana ecosystem and its role as a key decentralized AI infrastructure project. Community sentiment remains highly bullish, with many focusing on its long-term potential as an AI supercomputer while actively debating staking strategies and the importance of subnet developments.

Anthropic

Anthropic is trending as investors and the community closely track its path toward a highly anticipated IPO, fueled by massive capital raises and intense competition with OpenAI. The discourse is heavily focused on the company's aggressive infrastructure scaling, its strategic partnerships with tech giants, and the ongoing debate regarding the government's role in regulating powerful AI systems.

OpenAI

OpenAI is trending as investors closely monitor reports of a potential IPO later this year, alongside community discussions regarding its recent cloud infrastructure acquisitions and strategic shift toward broader market reach. While market participants are actively debating the sustainability of high AI capital expenditures and competitive pressures from rivals like Anthropic, the ongoing legal proceedings involving Sam Altman have added a layer of scrutiny to the company's governance and future market debut.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgen is trending due to the FDA's full approval of Imdelltra for small-cell lung cancer, which offers a significant survival benefit for patients who have progressed after initial chemotherapy. The community is also closely monitoring the company's cardiometabolic portfolio and ongoing clinical data, while actively debating the potential for M&A activity within the obesity drug space.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

Internet Computer (ICP) is currently trending as investors focus on its potential as a sovereign cloud infrastructure alternative to Big Tech, driven by ongoing deployments like the Pakistan subnet and the anticipation of new product rollouts. Community discourse reflects a split between long-term holders encouraged by fundamental network growth and utility, and skeptical traders wary of historical volatility and price performance.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors react to a $180 million public offering following strong Phase 3 results for its CRISPR-based HAE therapy, fueling debates between those highlighting the clinical de-risking and others frustrated by shareholder dilution. Community sentiment is sharply divided, with bulls pointing to the company's long-term commercial potential and institutional accumulation, while bears emphasize the timing of the offering and ongoing volatility in the heavily shorted stock.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

Cosmos is generating significant buzz as investors weigh the potential impact of legislative developments like the Clarity Act against the token's high staking rewards. Community discourse remains divided, with active debates focusing on long-term utility, persistent price stagnation, and the contrast between aggressive staking strategies and bearish sentiment surrounding recent performance.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending as investors monitor the commercial launch of NEREUS for motion sickness while debating potential buyout interest from pharmaceutical giants like Eli Lilly. Community members are actively discussing the company's GLP-1 adjunct pipeline and expressing frustration over recent price volatility and management's aggressive regulatory stance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rigel to Present at the Jefferies Global Healthcare Conference

Rigel to Present at the Jefferies Global Healthcare Conference Rigel to Present at the Jefferies Global Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif., May 27, 2026 SOUTH SAN FRANCISCO, Calif., May 27, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial...

Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress

Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress PR Newswire SOUTH SAN FRANCISCO, Calif., May 21, 2026 Oral presentation at ASCO Annual Meeting to...

Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference

Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif...

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer following recent FDA approval.read more...

RIGL Stock Jumps 15%, Short Interest Surges To Record High – Why Is Retail Eyeing A Further 40% Upside?

Equity

Rigel Pharmaceuticals signed a global licensing deal with Arvinas and Pfizer for an advanced breast cancer treatment.

Rigel Pharma Signs Licensing Agreement With Arvinas And Pfizer For Veppanu

(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) on Tuesday said it has entered into a global license agreement with Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) to develop, manufacture and commercialize beast cancer treatment Veppanu...

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer Rigel Enters Exclusive...

Rigel Pharmaceuticals Q1 Earnings Call Highlights

Rigel Pharmaceuticals (NASDAQ:RIGL) reported first-quarter 2026 results that management said reflected continued year-over-year growth across its three-product portfolio, while reiterating full-year guidance and highlighting upcoming data milestones for its R289 program in lower-risk myelodysplastic...

Rigel Pharmaceuticals Inc. Profit Falls In Q1

(RTTNews) - Rigel Pharmaceuticals Inc. (RIGL) announced earnings for first quarter that Dropped, from last year...

Rigel Pharmaceuticals (NASDAQ:RIGL) Posts Quarterly Earnings Results

Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) released its earnings results on Tuesday. The biotechnology company reported $0.44 EPS for the quarter, missing analysts' consensus estimates of $0.80 by ($0.36). The firm had revenue of $58.82 million during the quarter, compared to analysts...

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

RIGLRigel Pharmaceuticals

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RIGL News